Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst; Giuseppe Giaccone; Filippo de Marinis; Niels Reinmuth; A. Vergnenègre; Carlos H. Barrios; Masahiro Morise; Enriqueta Felip; Zoran Andrić; Sarayut Lucien Geater; Mustafa Özgüroğlu; Wei Zou; Alan Sandler; Ida Enquist; Kimberly M. Komatsubara; Yu Deng; Hiroshi Kuriki; Xiaohui Wen; Mark L. McCleland; Simonetta Mocci; Jacek Jassem; David R. Spigel

doi:10.1056/nejmoa1917346

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of histologic type. (Funded by F. Hoffmann-La Roche/Genentech; IMpower110 ClinicalTrials.gov number, NCT02409342.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Herbst et al. (2020) studied this question.

synapsesocial.com/papers/6985ef823b00292770426f3b https://doi.org/10.1056/nejmoa1917346

View Full Paper

Ask AI

Bookmark

Share

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading